Oncotarget · 2014 · 29 citations · 27 references
MedicineMolecular BiologyOncologyCancer GeneticsCarcinogenesisMolecular OncologyCancer Cell SignalingCancer Stem CellsComputational OncologyMolecular Tumor ProfilingOncogenic Signaling PathwaysTumor BiologyCancer BioinformaticsComputational Network ModelingHippo SignalingHippo Signaling PathwayMalignant ProgressionOncogenic Signaling NetworksTriple-negative Breast Cancer TherapyTumor Initiating Cells
// Costa Frangou 1, * , Ying-Wei Li 1, * , He Shen 1 , Nuo Yang 1 , Kayla E. Wilson 1 , Maxime Blijlevens 1 , Jin Guo 1 , Norma J. Nowak 2 , Jianmin Zhang 1 1 Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA 2 Department of Biochemistry, School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA * These authors contributed equally to this work Correspondence to: Jianmin Zhang, e-mail: jianmin.zhang@roswellpark.org Keywords: breast cancer, TAZ, tumor-initiating cells, RNA sequencing, Dasatinib Received: August 07, 2014 Accepted: October 03, 2014 Published: October 24, 2014 ABSTRACT Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancer (BC) cases and contributes disproportionately to BC mortality. TAZ, a key transducer of the Hippo pathway, has recently been demonstrated to confer breast cancer stem cell (CSC) traits. However, TAZ target genes and the underlying transcriptional regulatory pathways responsible for the CSC phenomenon remain unknown. Here, we demonstrate that the oncogenic activity of TAZ is essential for propagation of the malignant phenotype. We further show that constitutively active TAZ tumor-derived cells exhibit unique tumor-initiating properties, including increased self-renewal and metastatic seeding potential, acquired chemotherapy resistance and the ability to efficiently regenerate tumor formation in vivo . Combined digital RNA expression analysis and computational network approaches identify several signaling pathways that distinguish breast cancer tumor-initiating cells (T-ICs) from bulk tumor cells. We demonstrate the utility of this approach by repositioning the small molecule tyrosine kinase inhibitor, Dasatinib, which selectively targets T-ICs and inhibits TNBC growth in vivo .
27
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Glynn Dennis, Brad T. Sherman, Douglas A Hosack et al. · Genome biology · 2003 · 9.5K citations · Full text
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A. Mani, Wenjun Guo, Mai-Jing Liao et al. · Cell · 2008 · 8.7K citations · Full text
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu, Aditya Bardia, Ben S. Wittner et al. · Science · 2013 · 2.5K citations
Medicine, Cell Biology, Oncology +12
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Daniele Merico, Ruth Isserlin, Oliver Stueker et al. · PLoS ONE · 2010 · 2.4K citations · Full text